Abstract
Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and complex, leading to poor prognoses and creating a need for new treatment modalities. Aberrant epigenetics define these types of tumors, with underlying changes in DNA methylation, histone modifications, chromatin structure and noncoding RNAs. Epigenetic-targeted therapies are an alternative that have the potential to reverse the epigenetic deregulation underpinning brain malignancies. Various drugs targeting epigenetic regulators have shown promise in preclinical and clinical testing. In this review, we highlight some of the recent emerging epigenetic targeted therapies for brain tumors being evaluated in the discovery phase and in clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Not applicable.
Code Availability
Not applicable.
References
Alrfaei, B. M., Clark, P., Vemuganti, R., & Kuo, J. S. (2020). MicroRNA miR-100 decreases glioblastoma growth by targeting SMARCA5 and ErbB3 in tumor-initiating cells. Technology in Cancer Research & Treatment, 19, 1533033820960748. https://doi.org/10.1177/1533033820960748
Alrfaei, B. M., Vemuganti, R., & Kuo, J. S. (2013). microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models. PLoS ONE, 8(11), e80865. https://doi.org/10.1371/journal.pone.0080865
Ambros, V. (2004). The functions of animal microRNAs. Nature, 431(7006), 350–355. https://doi.org/10.1038/nature02871
Bharambe, H. S., Joshi, A., Yogi, K., Kazi, S., & Shirsat, N. V. (2020). Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma. Acta Neuropathologica Communications, 8(1), 70. https://doi.org/10.1186/s40478-020-00942-5
Borodovsky, A., Salmasi, V., Turcan, S., Fabius, A. W., Baia, G. S., Eberhart, C. G., et al. (2013). 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 4(10), 1737–1747. https://doi.org/10.18632/oncotarget.1408
Brower, J. V., Clark, P. A., Lyon, W., & Kuo, J. S. (2014). MicroRNAs in cancer: Glioblastoma and glioblastoma cancer stem cells. Neurochemistry International, 77, 68–77. https://doi.org/10.1016/j.neuint.2014.06.002
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., et al. (2019). Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduction and Targeted Therapy, 4, 62. https://doi.org/10.1038/s41392-019-0095-0
Costa, F. F., Bischof, J. M., Vanin, E. F., Lulla, R. R., Wang, M., Sredni, S. T., et al. (2011). Identification of microRNAs as potential prognostic markers in ependymoma. PLoS ONE, 6(10), e25114. https://doi.org/10.1371/journal.pone.0025114
Dambal, S., Shah, M., Mihelich, B., & Nonn, L. (2015). The microRNA-183 cluster: The family that plays together stays together. Nucleic Acids Research, 43(15), 7173–7188. https://doi.org/10.1093/nar/gkv703
Duchatel, R. J., Jackson, E. R., Alvaro, F., Nixon, B., Hondermarck, H., & Dun, M. D. (2019). Signal transduction in diffuse intrinsic pontine glioma. Proteomics, 19(21–22), e1800479. https://doi.org/10.1002/pmic.201800479
El-Gewely, M. R., Andreassen, M., Walquist, M., Ursvik, A., Knutsen, E., Nystad, M., Coucheron, D. H., Myrmel, K. S., Hennig, R., & Johansen, S. D. (2016). Differentially expressed MicroRNAs in meningiomas Grades I and II suggest shared biomarkers with malignant tumors. Cancers (basel). https://doi.org/10.3390/cancers8030031
Esteller, M. (2011). Non-coding RNAs in human disease. Nature Reviews Genetics, 12(12), 861–874. https://doi.org/10.1038/nrg3074
Furuta, T., Sabit, H., Dong, Y., Miyashita, K., Kinoshita, M., Uchiyama, N., et al. (2017). Biological basis and clinical study of glycogen synthase kinase- 3beta-targeted therapy by drug repositioning for glioblastoma. Oncotarget, 8(14), 22811–22824. https://doi.org/10.18632/oncotarget.15206
Galbraith, K., Kumar, A., Abdullah, K. G., Walker, J. M., Adams, S. H., Prior, T., Dimentberg, R., Henderson, F. C., Mirchia, K., Sathe, A. A., Viapiano, M. S., Chin, L. S., Corona, R. J., Hatanpaa, K. J., Snuderl, M., Xing, C., Brem, S., & Richardson, T. E. (2020). Molecular correlates of long survival in IDH-wildtype glioblastoma cohorts. Journal of Neuropathology and Experimental Neurology, 79(8), 843–854. https://doi.org/10.1093/jnen/nlaa059
Gartel, A. L., & Kandel, E. S. (2008). miRNAs: Little known mediators of oncogenesis. Seminars in Cancer Biology, 18(2), 103–110. https://doi.org/10.1016/j.semcancer.2008.01.008
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019). Epigenetic heterogeneity in cancer. Biomark Res, 7, 23. https://doi.org/10.1186/s40364-019-0174-y
Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020). IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets. British Journal of Cancer, 122(11), 1580–1589. https://doi.org/10.1038/s41416-020-0814-x
Kernytsky, A., Wang, F., Hansen, E., Schalm, S., Straley, K., Gliser, C., et al. (2015). IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood, 125(2), 296–303. https://doi.org/10.1182/blood-2013-10-533604
Kraus, W. L., & Hottiger, M. O. (2013). PARP-1 and gene regulation: Progress and puzzles. Molecular Aspects of Medicine, 34(6), 1109–1123. https://doi.org/10.1016/j.mam.2013.01.005
Kreth, S., Thon, N., & Kreth, F. W. (2014). Epigenetics in human gliomas. Cancer Letters, 342(2), 185–192. https://doi.org/10.1016/j.canlet.2012.04.008
Lee, S. Y. (2016). Temozolomide resistance in glioblastoma multiforme. Genes and Diseases, 3(3), 198–210. https://doi.org/10.1016/j.gendis.2016.04.007
Long, W., Yi, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017). Potential new therapies for pediatric diffuse intrinsic pontine glioma. Frontiers in Pharmacology, 8, 495. https://doi.org/10.3389/fphar.2017.00495
Lourdusamy, A., Rahman, R., Smith, S., & Grundy, R. (2015). microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. Acta Neuropathologica Communications, 3, 26. https://doi.org/10.1186/s40478-015-0206-2
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2016). An epigenetic gateway to brain tumor cell identity. Nature Neuroscience, 19(1), 10–19. https://doi.org/10.1038/nn.4190
Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E., De La Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H., Janku, F., Young, R. J., Huang, R., Jiang, L., Choe, S., Fan, B., Yen, K., Lu, M., Bowden, C., Steelman, L., & Pandya, S. S. (2020). Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. Journal of Clinical Oncology, 38(29), 3398–3406. https://doi.org/10.1200/JCO.19.03327
Milde, T., Oehme, I., Korshunov, A., Kopp-Schneider, A., Remke, M., Northcott, P., Deubzer, H. E., Lodrini, M., Taylor, M. D., von Deimling, A., Pfister, S. & Witt, O. (2010). HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth. Clinical Cancer Research, 16(12), 3240–3252. https://doi.org/10.1158/1078-0432.CCR-10-0395
Mir, S. E., Smits, M., Biesmans, D., Julsing, M., Bugiani, M., Aronica, E., Kaspers, G. J. L., Cloos, J., Würdinger, T. & Hulleman, E. (2017). Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma. Oncotarget, 8(45), 78978–78988. https://doi.org/10.18632/oncotarget.20741
Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Hojfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse B. T., Tvardovskiy, A., Jensen, O. N., Olaciregui, N. G., Lavarino, C., Suñol, M., Torres, C. D., Mora, J., Carcaboso, A. M., & Helinet, K. (2017). EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nature Medicine, 23(4), 483–492. https://doi.org/10.1038/nm.4293
Mollashahi, B., Aghamaleki, F. S., & Movafagh, A. (2019). The roles of miRNAs in medulloblastoma: A systematic review. Journal of Cancer Prevention, 24(2), 79–90. https://doi.org/10.15430/JCP.2019.24.2.79
Moller, H. G., Rasmussen, A. P., Andersen, H. H., Johnsen, K. B., Henriksen, M., & Duroux, M. (2013). A systematic review of microRNA in glioblastoma multiforme: Micro-modulators in the mesenchymal mode of migration and invasion. Molecular Neurobiology, 47(1), 131–144. https://doi.org/10.1007/s12035-012-8349-7
Nagarajan, R. P., & Costello, J. F. (2009). Epigenetic mechanisms in glioblastoma multiforme. Seminars in Cancer Biology, 19(3), 188–197. https://doi.org/10.1016/j.semcancer.2009.02.005
Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Cliford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., Gajjar, A. & Pfister, S. M. (2019). Medulloblastoma. Nature Reviews. Disease Primers, 5(1), 11. https://doi.org/10.1038/s41572-019-0063-6
O’Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (lausanne), 9, 402. https://doi.org/10.3389/fendo.2018.00402
Ostrom, Q. T., Cioi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., Barnholtz-Sloan, J. S. (2019). CBTRUS statistical report: PRIMARY brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncology, 21(Suppl 5), v1–v100. https://doi.org/10.1093/neuonc/noz150
Pellegatta, S., Valletta, L., Corbetta, C., Patane, M., Zucca, I., Riccardi Sirtori, F., et al. (2015). Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathologica Communications, 3, 4. https://doi.org/10.1186/s40478-014-0180-0
Petrescu, G. E. D., Sabo, A. A., Torsin, L. I., Calin, G. A., & Dragomir, M. P. (2019). MicroRNA based theranostics for brain cancer: Basic principles. Journal of Experimental & Clinical Cancer Research, 38(1), 231. https://doi.org/10.1186/s13046-019-1180-5
Pyko, I. V., Nakada, M., Sabit, H., Teng, L., Furuyama, N., Hayashi, Y., Kawakami, K., Minamoto, T., Fedulau, A. S. & Hamada, J-I. (2013). Glycogen synthase kinase 3beta inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis, 34(10), 2206–2217. https://doi.org/10.1093/carcin/bgt182
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, Clark, O., Oldrini, B., Komisopoulou, E., Kunii, K., Pedraza, A., Schalm, S., Silverman, L., Miller, A., Wang, F., Yang, H., Chen, Y., Kernytsky, A., Marc, K. R., Liu, W., Biller, S. A., Shinsan M Su, S. M., Cameron W Brennan, C. W., Timothy A Chan, T. A., Graeber, T. G., Yen, K. E. & Mellinghoff I. K. (2013). An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science, 340(6132), 626–630. https://doi.org/10.1126/science.1236062
Romani, M., Pistillo, M. P., & Banelli, B. (2018). Epigenetic targeting of glioblastoma. Frontier Oncologia, 8, 448. https://doi.org/10.3389/fonc.2018.00448
Saydam, O., Shen, Y., Wurdinger, T., Senol, O., Boke, E., James, M. F., et al. (2009). Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Molecular and Cellular Biology, 29(21), 5923–5940. https://doi.org/10.1128/MCB.00332-09
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., Keil, M., Balß, J., Rauschenbach, K., Grabowska, A. K., Vogler, I., Diekmann, J., Trautwein, N., Eichmüller, S. B., Okun, J., Stevanović, S., Riemer, A. B., Sahin, U., Friese, M. A., Beckhove, P., von Deimling, A., Wick, W. & Platten, M.(2014). A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 512(7514), 324–327. https://doi.org/10.1038/nature13387
Shenouda, S. K., & Alahari, S. K. (2009). MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer and Metastasis Reviews, 28(3–4), 369–378. https://doi.org/10.1007/s10555-009-9188-5
Silber, J., Hashizume, R., Felix, T., Hariono, S., Yu, M., Berger, M. S., et al. (2013). Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro-Oncology, 15(1), 83–90. https://doi.org/10.1093/neuonc/nos281
Skalsky, R. L., & Cullen, B. R. (2011). Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE, 6(9), e24248. https://doi.org/10.1371/journal.pone.0024248
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D., Lhermitte, B., et al. (2017). Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA, 318(23), 2306–2316. https://doi.org/10.1001/jama.2017.18718
Tamimi, A. F., & Juweid, M. (2017). Epidemiology and outcome of glioblastoma. In S. De Vleeschouwer (Ed.), Glioblastoma. Brisbane: Codon Publications.
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Cliford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathologica, 123(4), 465–472. https://doi.org/10.1007/s00401-011-0922-z
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K. & Chan, T. A (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483(7390), 479–483. https://doi.org/10.1038/nature10866
van Vuurden, D. G., Hulleman, E., Meijer, O. L., Wedekind, L. E., Kool, M., Witt, H., Vandertop, P. W., Würdinger, T., Noske, D. P., Kaspers, G. J. L. & Cloos, J. (2011). PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget, 2(12), 984–996. https://doi.org/10.18632/oncotarget.362
Warren, K. E. (2012). Diffuse intrinsic pontine glioma: Poised for progress. Frontiers in Oncology, 2, 205. https://doi.org/10.3389/fonc.2012.00205
Wei, J., Nduom, E. K., Kong, L. Y., Hashimoto, Y., Xu, S., Gabrusiewicz, K., Ling, X., Huang, N., Qiao, W., Zhou, S., Ivan, C., Fuller, G. N., Gilbert, M. R., Overwijk, W., Calin, G. A. & Heimberger, A. B. (2016). MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology, 18(5), 639–648. https://doi.org/10.1093/neuonc/nov292
Witthayanuwat, S., Pesee, M., Supaadirek, C., Supakalin, N., Thamronganantasakul, K., & Krusun, S. (2018). Survival Analysis of Glioblastoma Multiforme. Asian Pacific Journal of Cancer Prevention, 19(9), 2613–2617. https://doi.org/10.22034/APJCP.2018.19.9.2613
Wu, J., Armstrong, T. S., & Gilbert, M. R. (2016). Biology and management of ependymomas. Neuro-Oncology, 18(7), 902–913. https://doi.org/10.1093/neuonc/now016
Yang, N. (2015). An overview of viral and nonviral delivery systems for microRNA. International Journal of Pharmaceutical Investigation, 5(4), 179–181. https://doi.org/10.4103/2230-973X.167646
Yeh, M., Oh, C. S., Yoo, J. Y., Kaur, B., & Lee, T. J. (2019). Pivotal role of microRNA-138 in human cancers. American Journal of Cancer Research, 9(6), 1118–1126.
Zhang, R. R., & Kuo, J. S. (2017). Reduced H3K27me3 is a new epigenetic biomarker for pediatric posterior fossa ependymomas. Neurosurgery, 81(1), N7–N8. https://doi.org/10.1093/neuros/nyx262
Acknowledgements
The authors would like to thank the Kuo lab members for their comments on the manuscript.
Funding
Funding support is appreciated from Dell Medical School, Mulva Clinic for the Neurosciences, LIVESTRONG Cancer Institutes and UT Austin.
Author information
Authors and Affiliations
Contributions
Conception and design (LK, VRI, JSK), Literature search (LK, CL, SE), Manuscript preparation (LK, CL, SE, VRI, JSK), Final approval (VRI, JSK).
Corresponding author
Ethics declarations
Conflict of interest
Not applicable.
Ethics Approval
Not applicable.
Consent for Publication
Not applicable.
Consent to Participate
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kukreja, L., Li, C.J., Ezhilan, S. et al. Emerging Epigenetic Therapies for Brain Tumors. Neuromol Med 24, 41–49 (2022). https://doi.org/10.1007/s12017-021-08691-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-021-08691-x